David Hovland

General Counsel at ELEDON PHARMACEUTICALS, INC.

Health Technology

Consumer Services

Profile

David Hovland is currently the Chief Regulatory Officer at Eledon Pharmaceuticals, Inc. Prior to this, he was the Senior Vice President-Global Regulatory Affairs at Urovant Sciences Ltd.
from 2018 to 2021.
He was also the Vice President-Global Regulatory Affairs at Allergan Ltd.
(Ireland) from 2015 to 2018.
Before that, he was the Director-Global Regulatory Affairs at Amgen, Inc. from 2006 to 2010.
He started his career as a Study Director at Allergan Ltd.
(Ireland) from 1999 to 2002.
Dr. Hovland holds a doctorate degree from the University of California, Los Angeles and an undergraduate degree from the University of California, Berkeley.

David Hovland active positions

Companies	Position	Start
ELEDON PHARMACEUTICALS, INC.	General Counsel	2021-04-18

All active positions of David Hovland

Former positions of David Hovland

Companies	Position	End
UROVANT SCIENCES LTD.	General Counsel	2021-03-31
ALLERGAN PLC	General Counsel	2017-12-31
AMGEN INC.	General Counsel	2009-12-31
ALLERGAN PLC	Corporate Officer/Principal	2001-12-31

See the detail of David Hovland's experience

Training of David Hovland

University of California, Los Angeles	Doctorate Degree
University of California, Berkeley	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David Hovland's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
AMGEN INC.	Health Technology
ELEDON PHARMACEUTICALS, INC.	Health Technology

Private companies	2
Allergan Ltd. (Ireland) Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.	Health Technology
Urovant Sciences Ltd. Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom.	Health Technology

Private companies